ReviewFrontiers in cell and developmental biology2021
The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis.Stem cell research & therapy · 2024Pooled it
- Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis.Cell transplantationPooled it
- Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.ESC heart failure · 2023Trial
- Engineering cardiac regeneration using stem cells: Cellular sources, differentiation signatures, targeted delivery, and functional recovery.Regenerative therapy · 2026Review
- Biofabrication strategies for engineered constructs in cardiovascular tissue repair.Regenerative therapy · 2026Review
- Review
- Cardiac function and mortality of stem cell therapy in patients with coronary artery disease who underwent coronary artery bypass graft without heart failure: A meta-analysis.Biomedical reports · 2025Article
- DNA Aptamer-Guided Glycomimetics for Developmental Stage-Specific Glycocalyx Engineering to Control Stem Cell Differentiation.Journal of the American Chemical Society · 2025Article
- Reprogramming of human urine cells into cardiomyocytes via a small molecule cocktail in xeno-free conditions.Communications medicine · 2025Article
- Multicellularity, Culture Duration, and Hydrogel Stiffness Guide Induced Pluripotent Stem Cell-Derived Endothelial Progenitor Cell Contractility.bioRxiv : the preprint server for biology · 2025Article
- PRMT1 inhibition enhances the cardioprotective effect of adipose-derived mesenchymal stem cells against myocardial infarction through RUNX1.Stem cell research & therapy · 2025Article
- Cell Reprogramming, Transdifferentiation, and Dedifferentiation Approaches for Heart Repair.International journal of molecular sciences · 2025Review
- Engineering a robust and anisotropic cardiac-specific extracellular matrix scaffold for cardiac patch tissue engineering.Matrix biology plus · 2024Article
- Laminin Alpha 2 Enhances the Protective Effect of Exosomes on Human iPSC-Derived Cardiomyocytes in an In Vitro Ischemia-Reoxygenation Model.International journal of molecular sciences · 2024Article
- To Repair a Broken Heart: Stem Cells in Ischemic Heart Disease.Current issues in molecular biology · 2024Review
- Application and challenges of stem cells in cardiovascular aging.Regenerative therapy · 2024Review
- The past, present, and future promise of pluripotent stem cells.Journal of immunology and regenerative medicine · 2024Article
- Cell sheet transplantation for ischemic heart disease: a systematic review.Indian journal of thoracic and cardiovascular surgery · 2023Article
- Review
- Stem cells treatment in chronic ischemic heart disease: a narrative review.American journal of stem cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease (IHD) is the leading cause of mortality worldwide. Stem cell transplantation has become a promising approach for the treatment of IHD in recent decades. It is generally recognized that preclinical cell-based therapy is effective and have yielded encouraging results, which involves preventing or reducing myocardial cell death, inhibiting scar formation, promoting angiogenesis, and improving cardiac function. However, clinical studies have not yet achieved a desired outcome, even multiple clinical studies showing paradoxical results. Besides, many fundamental puzzles remain to be resolved, for example, what is the optimal delivery timing and approach? Additionally, limited cell engraftment and survival, challenging cell fate monitoring, and not fully understood functional mechanisms are defined hurdles to clinical translation. Here we review some of the current dilemmas in stem cell-based therapy for IHD, along with our efforts and opinions on these key issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.